VA
NXTC icon

Verdad Advisers’s NextCure NXTC Stock Holding History

Verdad Advisers’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$459K Buy
+42,955
New +$525K 0.52% 72

Other funds holding NXTC

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Verdad Advisers's NXTC Position: Q1 2026 in Review

Verdad Advisers opened a new position in NextCure (NXTC) in Q1 2026: 42,955 shares worth $459K. The stake represents 0.52% of the portfolio and ranks #72 among its holdings.

26 funds tracked by Wall St. Rank hold NXTC as of Q1 2026.

  • Verdad Advisers held 42,955 shares of NextCure worth $459K as of Q1 2026.
  • NextCure was a new Verdad Advisers position in Q1 2026.
  • NextCure made up 0.52% of Verdad Advisers's portfolio in Q1 2026, its #72 holding.
  • 26 funds tracked by Wall St. Rank held NextCure as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.